本文選題：化療相關(guān)性腹瀉 + 益生菌　； 參考：《中國(guó)藥房》2017年09期

【摘要】：目的:系統(tǒng)評(píng)價(jià)益生菌輔助防治化療相關(guān)性腹瀉(CID)的有效性,為臨床提供循證參考。方法:計(jì)算機(jī)檢索EMBase、Cochrane圖書(shū)館、Pub Med、相關(guān)期刊論文、中文科技期刊數(shù)據(jù)庫(kù)、萬(wàn)方數(shù)據(jù)庫(kù)和中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù),收集益生菌輔助防治CID的隨機(jī)對(duì)照試驗(yàn)(RCT),提取資料并根據(jù)Cochrane Hand book 5.0推薦的"風(fēng)險(xiǎn)偏倚評(píng)估"工具評(píng)價(jià)質(zhì)量,采用Rev Man5.2統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果:最終納入10項(xiàng)RCT,共871例患者。Meta分析結(jié)果顯示,在常規(guī)對(duì)癥治療的基礎(chǔ)上加用益生菌可以顯著降低腫瘤患者總腹瀉率[OR=0.31,95%CI(0.20,0.49),P0.001]和Ⅲ~Ⅳ級(jí)腹瀉率[OR=0.09,95%CI(0.03,0.24),P0.001],提高總有效率[OR=4.16,95%CI(2.40,7.23),P0.001]和完全緩解率[OR=2.55,95%CI(1.66,3.90),P0.001],差異均有統(tǒng)計(jì)學(xué)意義;但對(duì)患者Ⅰ~Ⅱ級(jí)腹瀉率[OR=0.86,95%CI(0.48,1.56),P=0.62]和部分緩解率[OR=1.00,95%CI(0.67,1.50),P=1.00]影響不大,差異均無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論:化療前使用益生菌可有效預(yù)防腫瘤患者嚴(yán)重CID的發(fā)生;在治療CID中,聯(lián)用益生菌亦可以提高常規(guī)對(duì)癥治療的療效。
[Abstract]:Objective: to evaluate the efficacy of probiotics in the prevention and treatment of chemotherapy-associated diarrhea. Methods: a computer-based search was conducted for Pub Med, Chinese Journal Full-text Database, Chinese Sci-tech Journal Database, Wanfang Database and Chinese Biomedical Literature Database. A randomized controlled trial of probiotics assisted control of CID was collected. The data were extracted and evaluated according to the "risk bias assessment" tool recommended by Cochrane Hand book 5.0. Meta analysis was carried out with Rev Man5.2 statistical software. Results: a total of 871 patients were included in 10 RCTs. Meta-analysis showed that, However, there was no significant difference in the rates of 鈪，

本文編號(hào)：1774876